Department of Pharmacy Practice and Science
University of Kentucky
Director of Oncology and Infusion Pharmacy
Markey Cancer Center
UK Health Care
Thoracic Oncology Program
Swedish Cancer Institute
Associate Managing Editor
Senior Clinical Editor
Editorial Director, Hematology/Oncology
Senior Managing Editor
This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with non-small-cell lung cancer.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-18-084-H01-P
Type of Activity: Knowledge
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 23, 2018, through April 22, 2019:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.
Phase II results of poziotinib in patients with heavily pretreated EGFR or HER2 exon 20–mutated NSCLC from WCLC 2018 reported by Clinical Care Options (CCO).
Results of ALTER1202 trial show significant PFS benefit with anlotinib for patients with SCLC who progressed after 2 lines of chemotherapy from WCLC 2018 reported by Clinical Care Options (CCO).
Entrectinib in ROS1-positive NSCLC showed substantial activity, even in patients with CNS metastases in an analysis of 3 early studies from WCLC 2018 reported by Clinical Care Options (CCO)
10-year mortality results from NELSON study in high-risk smokers followed with low-dose CT screening from WCLC 2018 reported by Clinical Care Options (CCO).
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.